JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
ご注意
現在、日本語に対応しているのは、Luminex LTGのセクションとLuminex LTGのサービス&サポートページのみです。
Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese.
09/09/24 - 13:11
Diasorin launches the LIAISON® Streptococcus pneumoniae Ag Assay in all countries accepting the CE Mark (498.13 KB)
29/07/24 - 17:35
Diasorin: Publication of the documents for the Shareholders' Meeting scheduled on September 4, 2024 (135.08 KB)
29/07/24 - 15:55
DIASORIN RAISES FULL-YEAR 2024 GUIDANCE AS A RESULT OF THE POSITIVE PERFORMANCE OF THE FIRST SEMESTER OF THE YEAR (606.06 KB)
16/07/24 - 8:31
Diasorin receives FDA de-novo grant for the SIMPLEXA® C. auris Direct assay on the LIAISON® MDX instrument (546.76 KB)
05/06/24 - 5:07
Diasorin receives FDA 510(k) clearance for the LIAISON PLEX® Blood Culture Yeast Assay on the new multiplexing LIAISON PLEX® (693.98 KB)
16/05/24 - 19:56
Diasorin receives FDA 510(k) clearance for the updated syndromic panel NxTAG® Respiratory Pathogen Panel v2 (500.66 KB)
10/05/24 - 17:54
Restart of the buyback program (108.54 KB)
10/05/24 - 15:21
Q1 Revenues and Adjusted EBITDA in line with the high range of the FY’24 Guidance (689.42 KB)
24/04/24 - 15:38
Shareholders' Meeting 2024 (159.72 KB)
16/04/24 - 8:20
Communication on total amount of voting rights (135.47 KB)
04/04/24 - 9:34
DiaSorin S.p.A.- Update 2024 Annual Calendar of Corporate Events (103.76 KB)
15/03/24 - 17:14
Diasorin: Publication of the documents for the Ordinary Shareholders' Meeting scheduled on April 24, 2024 (135.35 KB)
15/03/24 - 13:35
The Board of Directors of Diasorin SpA approves FY2023 Results; proposed ordinary dividend of € 1.15 per share (401.32 KB)
13/03/24 - 10:23
Diasorin submits LIAISON PLEX® Yeast Blood Culture Assay for the LIAISON PLEX® system to the U.S. FDA (530.89 KB)
03/03/24 - 19:32
Diasorin receives FDA 510(K) clearance for its LIAISON PLEX® system together with the LIAISON PLEX® Respiratory Panel (150.83 KB)
25/01/24 - 7:48
Diasorin announces that it submitted the LIAISON® LymeDetect® to the U.S. Food and Drug Administration in December 2023 (507.38 KB)
18/01/24 - 12:30
2024 Annual Calendar of Corporate Events (115.8 KB)
15/12/23 - 17:38
Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
06/11/23 - 15:44
Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
03/11/23 - 15:51
Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
24/10/23 - 15:03
Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
27/07/23 - 14:27
Update 2023 Annual Calendar of Corporate Events (104.1 KB)
27/07/23 - 13:18
Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
17/07/23 - 7:03
DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
03/07/23 - 11:48
Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
13/06/23 - 15:18
DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
07/06/23 - 14:40
Communication of total amount of voting rights (7 June 2023) (141.14 KB)
05/06/23 - 21:58
Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
26/05/23 - 7:10
DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
09/05/23 - 11:56
Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
28/04/23 - 12:52
Shareholders' Meeting 2023 (373.48 KB)
27/03/23 - 15:52
Update 2023 Annual Calendar of Corporate Events (483.89 KB)
27/03/23 - 14:38
Dividend coupon date correction (493.46 KB)
27/03/23 - 13:35
REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
17/03/23 - 22:05
DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
28/02/23 - 16:06
Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
13/02/23 - 22:03
CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
07/02/23 - 12:01
Update 2023 Annual Calendar of Corporate Events (288.3 KB)
01/12/22 - 18:30
2023 Annual Calendar of Corporate Events (288 KB)
09/11/22 - 7:04
DiaSorin Simplexa® cCMV Direct assay received U.S. FDA 510(K) clearance (134.99 KB)
07/11/22 - 7:12
DiaSorin commercializes molecular reagent for monkeypox virus (149 KB)
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
05/10/22 - 6:37
DiaSorin furthers its collaboration with BARDA for the LIAISON® NES (160.31 KB)
14/09/22 - 0:29
DIASORIN SIMPLEXA™ COVID-19 TEST RECEIVED U.S. FDA 510(K) CLEARANCE (194.22 KB)
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
14/07/22 - 20:00
DiaSorin receives FDA 510(k) clearance for its LIAISON® MeMed BV® test (160.88 KB)
07/06/22 - 18:06
Execution of the project for the redefinition of the corporate structure of DiaSorin (286.22 KB)
20/05/22 - 7:08
DiaSorin CE Marks their ARIES® Flu A/B & RSV+SARS-CoV-2 Lowplex Assay (106.16 KB)
09/05/22 - 7:02
DiaSorin and B·R·A·H·M·S, part of Thermo Fisher Scientific, partner to develop and commercialize the new LIAISON® B·R·A·H·M·S MR-proADM™ (173.49 KB)
06/05/22 - 17:33
Update 2022 Annual Calendar of Corporate Events (285.68 KB)
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
02/05/22 - 12:55
Publication of the summary report of the votes cast (280.95 KB)
29/04/22 - 16:26
Shareholders' meeting 2022 (166.12 KB)
22/04/22 - 12:37
New proposal for resolution related to the remuneration of the Board of Statutory Auditors (281.82 KB)
13/04/22 - 16:43
DiaSorin: Publication of the updated proxy forms for voting through the Designated Representative (282.86 KB)
08/04/22 - 19:13
Publication of the lists of candidates for the appointment of the Board of Directors, the Board of Statutory Auditors and relevant proposals for resolution (291.36 KB)
08/04/22 - 9:53
Update annual calendar of corporate events 2022 (288.09 KB)
05/04/22 - 9:51
Notice pursuant to art. 144-octies, paga 2 of Consob Regulation No. 11971/1999 (309.07 KB)
04/04/22 - 18:12
Filing of the lists submitted by IP Investimenti e Partecipazioni S.r.l. (577.98 KB)
16/03/22 - 17:39
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021 (404.69 KB)
08/03/22 - 7:13
DiaSorin announces CE Marking of the new NxTAG® Gastrointestinal Molecular Multiplex Pathogen Panel (105.47 KB)
13/01/22 - 7:24
DiaSorin releases an updated Simplexa™ SARS-CoV-2 Variants Direct molecular assay (RUO) for the detection of mutations associated with the Omicron variant (486.67 KB)
21/12/21 - 11:07
2022 Annual Calendar of Corporate Events (296.13 KB)
16/12/21 - 22:47
DiaSorin 2022-2025 Strategic Plan (552.15 KB)
30/11/21 - 19:10
DiaSorin confirms effectiveness of its Molecular Diagnostic tests in light of new Omicron SARS-CoV-2 Variant (307.83 KB)
29/11/21 - 7:06
DiaSorin receives FDA approval for its LIAISON® QuantiFERON®-TB Gold Plus assay for use on the LIAISON® XS Analyzer (437.79 KB)
23/11/21 - 7:10
DiaSorin launches LIAISON® MeMed BV®, the first high throughput blood test to differentiate between bacterial and viral infections, in countries accepting the CE Mark (412.77 KB)
11/11/21 - 16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
05/11/21 - 11:22
Weekly report treasury shares buy-back (2.15 MB)
02/11/21 - 20:00
Conclusion treasury shares buy-back plan (294.67 KB)
02/11/21 - 19:57
Weekly report treasury shares buy-back (3.5 MB)
27/10/21 - 16:35
Issuance of the "Physical Settlement Notice" (517.5 KB)
07/10/21 - 11:45
Publication of the summary report of the votes (290.08 KB)
04/10/21 - 12:27
The Extraordinary Shareholders' Meeting of DiaSorin authorizes the convertibility of the equity-linked bond and the share capital increase (297.73 KB)
18/09/21 - 8:16
DiaSorin CE Marks its new Simplexa™ COVID-19 & Flu A/B Direct Assay for Detection and Differentiation of SARS-CoV-2 and Influenza in One Test (407.21 KB)
30/07/21 - 18:43
Start up of the treasury shares buy-back plan (773.96 KB)
30/07/21 - 12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
22/07/21 - 18:28
Publication of Information Document under the provisions of the art. 71 of the CONSOB Regulation n. 11971/1999 (303.95 KB)
14/07/21 - 15:05
DiaSorin announces completion of the Acquisition of Luminex Corporation (566.52 KB)
09/07/21 - 7:34
DiaSorin obtains all approvals necessary to complete the acquisition of Luminex (560.68 KB)
21/06/21 - 18:49
The Shareholders’ meeting of Luminex Corporation approved the merger of Luminex with a U.S. wholly-owned subsidiary of DiaSorin (395.62 KB)
15/06/21 - 6:56
DiaSorin launches the first fully automated CLIA high-throughput solution for diagnosing Hepatitis E (307.58 KB)
07/06/21 - 15:16
Communication on total amount of voting rights (563.42 KB)
03/06/21 - 7:47
DiaSorin signs agreements with Unifarma and Alliance Healthcare for the distribution in Italian pharmacies of the LIAISON® IQ (523.42 KB)
25/05/21 - 7:03
DiaSorin: launch of the LIAISON® Quick Detect COVID Ag assay, an antigen test to detect COVID-19 infection (402.64 KB)
21/05/21 - 7:02
DiaSorin Releases an Assay for Rapid Identification of Mutations Associated with Circulating Variants of SARS-CoV-2 (393.69 KB)
20/05/21 - 8:27
DiaSorin’s LIAISON® SARS-CoV-2 TrimericS IgG test receives FDA Emergency Use Authorization for the U.S. market (506.2 KB)
14/05/21 - 16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
28/04/21 - 17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
28/04/21 - 7:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
22/04/21 - 15:58
Shareholders' meeting April 22, 2021 (422.91 KB)
21/04/21 - 7:02
DiaSorin, in partnership with QIAGEN, launches the new LIAISON® LymeDetect® Assay based on QuantiFERON technology (621.42 KB)
20/04/21 - 18:58
DiaSorin launches the LIAISON® IQ with a first test that detects IgG antibodies against SARS-COV-2 in markets accepting the CE Mark (403.5 KB)
14/04/21 - 10:05
Communication voting rights amount (544.6 KB)
12/04/21 - 11:08
Weekly report treasury shares buy-back (914.42 KB)
11/04/21 - 19:47
DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion (569.09 KB)
06/04/21 - 8:53
Start up buy-back plan (774.02 KB)
06/04/21 - 7:06
DiaSorin announces its strategic collaboration with Lumos Diagnostics (438.14 KB)
30/03/21 - 7:01
DiaSorin received BARDA funding to develop and achieve FDA regulatory authorization, for its LIAISON® SARS-CoV-2 Ag test (661.47 KB)
29/03/21 - 7:02
DiaSorin has obtained FDA Emergency Use Authorization for its LIAISON® SARS-CoV-2 Ag for COVID-19 testing in the U.S. (494.1 KB)
11/03/21 - 16:37
Dividend coupon date correction (414.99 KB)
11/03/21 - 15:31
Revenues, Profitability and Cash Flow Generation hit record highs in 2020 (748.06 KB)
23/02/21 - 6:11
DiaSorin obtained FDA approval for two additional serology tests for Lyme Disease in the U.S. market (413.92 KB)
27/01/21 - 18:50
2021 Annual Calendar of Corporate Events (209.87 KB)
11/01/21 - 18:43
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 TrimericS IgG test (418.29 KB)
29/12/20 - 18:22
DiaSorin has received BARDA Funding in support of submitting the SIMPLEXA COVID-19 Direct Kit for 510(k) clearance (400.67 KB)
17/12/20 - 17:57
DiaSorin - Policlinico San Matteo Hospital in Pavia vs. Technogenetics (298.96 KB)
07/12/20 - 10:35
Communication on total amount of voting rights (563.18 KB)
04/12/20 - 16:14
Form 3F (November 2020) (10.2 KB)
01/12/20 - 6:33
DiaSorin received FDA approval for its LIAISON® XL MUREX HIV Ab/Ag assay, completing the Hepatitis and Retrovirus offer in the US market (566.6 KB)
11/11/20 - 12:41
North America growth drives up revenues and profitability in the first 9 months of 2020 (805.25 KB)
26/10/20 - 18:30
DiaSorin launches with CE mark the LIAISON® SARS-CoV-2 Ag, a new high-throughput antigen test for COVID-19 detection in symptomatic patients (414.59 KB)
23/10/20 - 19:41
Conclusion treasury shares buy-back plan (314.28 KB)
23/10/20 - 19:37
Weekly report treasury shares buy-back (436.92 KB)
16/10/20 - 18:28
Weekly report treasury shares buy-back (425.19 KB)
01/10/20 - 7:45
DiaSorin received FDA approval on 6 Hepatitis B tests, completing its Hepatitis offer in the US market (395.31 KB)
01/10/20 - 7:32
DiaSorin’s LIAISON SARS-CoV-2 IgM test receives FDA Emergency Use Authorization for the U.S. market (488.09 KB)
23/09/20 - 7:16
DiaSorin extends its current joint venture with the Chinese Government to open a new manufacturing and research site in China (495.78 KB)
16/09/20 - 14:30
Update Annual Calendar of Corporate Events 2020 (222.26 KB)
16/09/20 - 7:25
DiaSorin Simplexa™ COVID-19 Direct molecular test CE marked for saliva specimens (477.67 KB)
08/09/20 - 7:31
DiaSorin and MeMed partner to develop and commercialize novel host immune response based diagnostics solution (506.16 KB)
07/09/20 - 18:22
FDA approval of Simplexa flu A_B & RSV Direct Gen II Assay (400.26 KB)
06/08/20 - 7:25
DiaSorin announces the launch of its new CE marked LIAISON Testosterone xt test for the dosage of testosterone (391.91 KB)
31/07/20 - 16:04
Weekly report treasury shares buy-back (380.16 KB)
30/07/20 - 13:16
North America business growth drives Group revenues and profitability in H1 2020 (735.54 KB)
24/07/20 - 17:19
Weekly report treasury shares buy-back (363.73 KB)
17/07/20 - 18:19
Weekly report treasury shares buy-back (360.09 KB)
10/07/20 - 18:23
Weekly report treasury shares buy-back (374 KB)
09/07/20 - 7:27
DiaSorin will provide the UK Government with its LIAISON SARS-CoV-2 S1/S2 IgG serology kit for COVID-19 testing to run a national screening study (399.63 KB)
07/07/20 - 7:22
DiaSorin CE marks their new Simplexa Flu A/B & RSV Direct Gen II Assay to run with the Simplexa COVID-19 Direct assay (490.1 KB)
30/06/20 - 7:25
DiaSorin announces the launch of its new LIAISON® SARS-COV-2 IgM test, a new fully automated serology kit available in Europe and in the U.S. to identify the immediate response to SARS-COV-2 in COVID-19 patients (397.37 KB)
19/06/20 - 17:20
Weekly report treasury shares buy-back (399.38 KB)
17/06/20 - 16:09
Start up of the treasury shares buy-back plan (481.28 KB)
12/06/20 - 7:30
DiaSorin has CE marked its molecular's Simplexa™ Congenital CMV Direct Assay (478.6 KB)
10/06/20 - 15:40
Shareholders' Meeting June 10, 2020 (308.25 KB)
03/06/20 - 14:16
The LIAISON® SARS-COV-2 S1/S2 IgG test received the approval for the commercialization in Brazil from ANVISA (397.21 KB)
02/06/20 - 14:58
Communication total amount voting rights (record date) (267.83 KB)
18/05/20 - 11:28
The LIAISON® SARS-COV-2 S1S2 IgG test is the first to receive the approval from Health Canada (308.26 KB)
13/05/20 - 13:15
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic (741.65 KB)
25/04/20 - 16:49
DiaSorin - FDA EUA and BARDA funding for SARS-CoV-2 IgG (403.66 KB)
17/04/20 - 18:25
DiaSorin has CE marked its SARS-COV-2 IgG serology kit for COVID-19 (464.49 KB)
07/04/20 - 7:14
IgG test to detect immune response to SARS-CoV-2 (394.92 KB)
26/03/20 - 18:14
Update Annual Calendar of Corporate Events 2020 (277.25 KB)
21/03/20 - 20:29
Shareholders' Meeting date change (288.23 KB)
20/03/20 - 7:28
DiaSorin COVID-19 test has received FDA Emergency Use Authorization (397.04 KB)
13/03/20 - 17:16
DiaSorin received BARDA funding to develop a rapid COVID-19 test (403.34 KB)
11/03/20 - 13:43
DiaSorin - Cash flow generation and net profit hit record highs in 2019 (919.6 KB)
10/03/20 - 8:20
DiaSorin - Development of Coronavirus test (404.03 KB)
02/03/20 - 8:04
DiaSorin signs an exclusive licensing agreement for molecular diagnostic POC technology (396.06 KB)
07/02/20 - 8:06
Communication on total amount of voting rights (281.13 KB)
15/01/20 - 16:51
Annual Calendar of Corporate Events 2020 (124.73 KB)
16/12/19 - 14:10
Diasorin receives FDA clearance for Simplexa VZV Swab Direct Molecular assay (571.47 KB)
06/12/19 - 18:12
Press Release (262.61 KB)
06/12/19 - 18:11
Press Release (262.7 KB)
06/12/19 - 18:08
Communication on total amount of voting rights (281.87 KB)
27/11/19 - 7:59
DIASORIN LAUNCHES THE LIAISON QUANTIFERON-TB GOLD PLUS ASSAY IN PARTNERSHIP WITH QIAGEN IN THE US MARKET (531.97 KB)
11/11/19 - 9:46
DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET (159.93 KB)
06/11/19 - 13:00
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019 (621.09 KB)
30/10/19 - 9:55
DIASORIN LAUNCHES LIAISON® XL ZIKA CAPTURE IgM II TEST FOR THE DETECTION OF ZIKA VIRUS IN THE US MARKET (579.27 KB)
22/10/19 - 14:10
DIASORIN LAUNCHES LIAISON HCV TEST FOR HEPATITIS C DIAGNOSIS IN THE US MARKET (358.37 KB)
07/10/19 - 10:20
Communication on total amount of voting rights (282.21 KB)
24/09/19 - 10:10
DiaSorin launches VZV Direct molecular test in Europe (369.67 KB)
31/07/19 - 13:00
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability. (687.57 KB)
10/06/19 - 18:23
DiaSorin presents its 2019-2022 Industrial Plan (548.2 KB)
05/06/19 - 7:38
DiaSorin and QIAGEN collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease (448.98 KB)
29/05/19 - 15:06
DiaSorin launches VZV DIRECT molecular test in the United States (360.87 KB)
09/05/19 - 13:14
DiaSorin Group reports growth in profitability and strong free cash flow generation in the first quarter 2019 (728.82 KB)
06/05/19 - 15:19
DiaSorin launches ELASTASE-1 test for the diagnosis of chronic exocrine pancreatitis on LIAISON XL (416.77 KB)
30/04/19 - 12:28
Update Annual Calendar of Corporate Events 2019 (249.43 KB)
24/04/19 - 17:24
DiaSorin: Shareholders' Meeting 2019 (449.66 KB)
12/04/19 - 8:59
Communication on total amount of voting rights (320.44 KB)
05/04/19 - 9:33
Communication on total amount of voting rights (342.47 KB)
03/04/19 - 20:18
Lists publication (79.68 KB)
03/04/19 - 10:32
DiaSorin launches the anaemia panel on Liaison XL in Europe (416.47 KB)
14/03/19 - 14:16
Growth in revenues, profitability and net profit in 2018 (1.03 MB)
07/03/19 - 11:45
Communication on total amount of voting rights (350.08 KB)
06/03/19 - 8:45
A new Group website for DiaSorin: www.diasoringroup.com (154.5 KB)
07/02/19 - 15:15
Communication on total amount of voting rights (February 7, 2019) (349.86 KB)
31/01/19 - 22:30
DiaSorin launches FDA-cleared LIAISON Calprotectin test in the US market (528.02 KB)
03/01/19 - 13:30
DiaSorin launches Simplexa Bordetella Direct Molecular test in the United States (428.56 KB)
21/12/18 - 11:30
DiaSorin launches 3 new primer pairs for use in molecular testing (438.25 KB)
04/12/18 - 8:00
DiaSorin's stocks listed in the FTSE MIB (464.63 KB)
19/11/18 - 15:00
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the United States (435.43 KB)
07/11/18 - 13:00
DiaSorin Group reports growth in revenues and net profit in the first nine months of 2018 (961.72 KB)
17/10/18 - 11:51
DiaSorin launches Simplexa Group B Strep Direct molecular assay in the european market (147.78 KB)
12/10/18 - 11:47
DiaSorin launches Simplexa VZV Direct molecular assay in the european market (444.81 KB)
09/10/18 - 11:35
DiaSorin and Meridian enter into a strategic collaboration to sell Helicobacter pylori stool antigen test in the United States and in the United Kingdom (471.21 KB)
17/09/18 - 11:28
DiaSorin launches the new LIASON quantiFERON-TB Gold Plus assay as an aid for latent tuberculosis detection in partnership with Qiagen (753.85 KB)
07/08/18 - 8:45
Communication on total amount of voting rights (305.24 KB)
02/08/18 - 12:45
The Board of Directors approves the results for the first half of 2018 (883.1 KB)
27/07/18 - 12:00
DiaSorin launches Hepatitis Delta (HDV) test on LIAISON XL platform (735.03 KB)
03/07/18 - 18:30
Conclusion treasury shares buy-back plan (397.33 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back July 2018) (6.59 KB)
03/07/18 - 18:30
Report treasury shares buy-back (287.99 KB)
03/07/18 - 18:30
Annex 3F (treasury shares buy back June 2018) (8.69 KB)
29/06/18 - 18:15
Weekly report treasury shares buy-back (290.62 KB)
22/06/18 - 20:30
Weekly report treasury shares buy-back (290.6 KB)
15/06/18 - 21:00
Weekly report treasury shares buy-back (290.62 KB)
12/06/18 - 14:15
DiaSorin introduces primer pair reagents for use in molecular testing: Anaplasma phagocytophilum, Ehrlichia e Babesia (445.17 KB)
08/06/18 - 23:15
Weekly report treasury shares buy-back (290.24 KB)
04/06/18 - 13:15
Annex 3F (treasury shares buy back May 2018) (8.54 KB)
01/06/18 - 20:15
Weekly report treasury shares buy-back (290.38 KB)
25/05/18 - 22:30
Weekly report treasury shares buy-back (289.97 KB)
19/05/18 - 1:45
Weekly report treasury shares buy-back (289.76 KB)
11/05/18 - 20:15
Weekly report treasury shares buy-back (290.77 KB)
08/05/18 - 14:30
The DiaSorin Group reports growth in revenues and profitability in the first quarter 2018 (832.84 KB)
03/05/18 - 20:15
Start up treasury shares buy-back plan (354.27 KB)
24/04/18 - 14:00
Annex 3F (treasury shares buy back) (7.77 KB)
23/04/18 - 18:30
Annual General Meeting 2018 (589.65 KB)
19/04/18 - 21:15
Conclusion treasury shares buy-back plan (397.59 KB)
19/04/18 - 21:00
Weekly report treasury shares buy-back (289.29 KB)
13/04/18 - 20:30
Weekly report treasury shares buy-back (290.07 KB)
06/04/18 - 19:45
Weekly report treasury shares buy-back (288.33 KB)
05/04/18 - 12:00
DiaSorin receives FDA clearance for the LIAISON BRAHMS PCT II GEN assay to detect severe bacterial infections (e.g. Sepsis) (737.88 KB)
04/04/18 - 20:00
Start up treasury shares buy-back plan (346.04 KB)
28/03/18 - 18:45
DiaSorin earns FDA clearence extending sample claims for Simplexa HSV 1 & 2 direct molecular test (442.69 KB)
07/03/18 - 15:30
DiaSorin: FY 2017 Results (1.14 MB)
30/01/18 - 11:45
DiaSorin signs an agreement with the Italian Tax Authority granting tax relief under the Italian Patent Box regime (574.68 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
08/01/18 - 9:00
QIAGEN and DiaSorin partner to offer fully automated tuberculosis detection with QuantiFERON-TB Gold Plus available on LIAISON analyzer systems (483.2 KB)
12/12/17 - 13:15
DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
29/11/17 - 19:30
Resignation of a Strategic Executive of the Company (233.58 KB)
09/11/17 - 14:15
GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
29/09/17 - 15:00
DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
29/09/17 - 14:15
DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
21/09/17 - 12:45
DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
03/08/17 - 14:45
DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
28/07/17 - 14:45
DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
25/07/17 - 21:00
DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
10/07/17 - 13:30
DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
26/06/17 - 9:45
DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
23/06/17 - 9:30
DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
22/06/17 - 19:45
DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
23/05/17 - 11:45
DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
16/05/17 - 13:00
DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
08/05/17 - 19:30
DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
27/04/17 - 18:45
DiaSorin - Annual General Meeting 2016 (421.04 KB)
21/04/17 - 18:45
DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
06/04/17 - 18:00
DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
08/03/17 - 15:30
The Board of Directors approves the results for FY'16 (1.13 MB)
21/02/17 - 11:30
DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
26/01/17 - 12:45
DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
19/12/16 - 10:00
Co-optation of a Director (333.18 KB)
10/11/16 - 1:00
DIASORIN GROUP REPORTS CONTINUED GROWTH IN REVENUES AND PROFITABILITY IN THE THIRD QUARTER 2016 (1.05 MB)
02/11/16 - 1:00
DIASORIN LAUNCHES ITS FIRST MOLECULAR TEST WITH THE NEW BUSINESS DIVISION, DIASORIN MOLECULAR: THE NEW SIMPLEXA C. DIFFICILE DIRECT MOLECULAR TEST (141.53 KB)
30/08/16 - 2:00
DiaSorin and Beckman Coulter form strategic partnership to bring the LIAISON XL hepatitis and HIV products to the U.S. market (404.63 KB)
22/08/16 - 2:00
DIASORIN PARTNERS WITH HHS TO FACE THE ZIKA EMERGENCY (158.39 KB)
04/08/16 - 2:00
The Board of Directors approves results for H1'16 (697.16 KB)
28/07/16 - 2:00
DiaSorin starts selling Vitamin D in Japan (724.4 KB)
14/07/16 - 2:00
DiaSorin increases diagnostic test menu for molecular screening of Acute Myeloid Leukemia (278.18 KB)
10/06/16 - 2:00
Weekly report treasury shares buy-back (289.83 KB)
10/06/16 - 2:00
Conclusion buy-back plan (367.77 KB)
07/06/16 - 2:00
DiaSorin launches the new Helicobacter pylori IgG CLIA test (518.61 KB)
03/06/16 - 2:00
Weekly report treasury shares buy-back (290.21 KB)
30/05/16 - 2:00
Notice filing By-Laws and publication operating procedures for loyalty shares (277.79 KB)
27/05/16 - 2:00
Weekly report treasury shares buy-back (289.34 KB)
20/05/16 - 2:00
Weekly report treasury shares buy-back (290.09 KB)
13/05/16 - 2:00
Acquisition of Focus Diagnostics' Molecular and Immunoassay Product Business (350.22 KB)
12/05/16 - 2:00
Start up treasury shares buy-back plan (305.9 KB)
09/05/16 - 2:00
The Board of Directors approves the results for Q1'16 (632.78 KB)
28/04/16 - 2:00
Shareholders' Meeting FY 2015 (365.15 KB)
30/03/16 - 2:00
DiaSorin to acquire Focus Diagnostics' Molecular and Immunoassay Product Business (133.62 KB)
09/03/16 - 1:00
The Board of Directors approves the results for FY'15 (785.08 KB)
11/11/15 - 1:00
The Board of Directors approves the results for Q3'15 (778.06 KB)
09/09/15 - 2:00
DiaSorin launches the two fastest molecular diagnostic tests in the world to detect fulminant leukemias (229.24 KB)
30/07/15 - 2:00
H1'15 Results (777.06 KB)
20/07/15 - 2:00
DiaSorin and Beckman Coulter sign a distribution agreement for China (238.01 KB)
28/05/15 - 2:00
DiaSorin launches the test for Campylobacter (241.86 KB)
12/05/15 - 2:00
The Board of Directors approves the results for Q1'15 (553.96 KB)
12/05/15 - 2:00
DiaSorin presents the 2015-2017 industrial plan (305.81 KB)
29/04/15 - 2:00
DiaSorin - launches the test for Brahms-Sepsis (506.96 KB)
23/04/15 - 2:00
DiaSorin supports the Pinocchio Project (251.16 KB)
22/04/15 - 2:00
The Board of Directors approves the 2015-2017 plan that will be presented at the Investor Day (141.85 KB)
22/04/15 - 2:00
Shareholders' meeting approves FY Results 2014 (105.93 KB)
14/04/15 - 2:00
DiaSorin launches the tests for Bordetella pertussis (187.11 KB)
10/04/15 - 2:00
Investor Day-save the date (107.93 KB)
24/03/15 - 1:00
DiaSorin in aid of Haiti's children in partnership with the Francesca Rava Foundation (504.27 KB)
03/03/15 - 1:00
The Board of Directors approves the results for FY'14 (783.03 KB)
24/02/15 - 1:00
DiaSorin supports Emergency in Sudan (612.64 KB)
13/02/15 - 1:00
DiaSorin teams with FISIP for Progetto talenti (612.64 KB)
14/01/15 - 1:00
DiaSorin launches the test for Calprotectin (259.67 KB)
16/12/14 - 1:00
FDA approves 1,25 Vitamin D in the US market (239.73 KB)
09/12/14 - 1:00
DiaSorin launches its first onco-hematology test on LIAISON Iam: the BCR-ABL (265.26 KB)
14/11/14 - 1:00
The Board of Directors approves the results for Q3'14 (785.42 KB)
07/10/14 - 2:00
DiaSorin launches the test for HIV HT on LIAISON (267.4 KB)
18/09/14 - 2:00
DiaSorin launches the stool test for Adenovirus on LIAISON (251.93 KB)
01/08/14 - 2:00
The Board of Directors approves the results for H1'14 (812.25 KB)
22/07/14 - 2:00
DIASORIN CONFIRMS ITS ELIGIBILITY FOR THE PEA-PME (148.49 KB)
30/06/14 - 2:00
DiaSorin launches the test for Herpes Simplex 1 and 2 on LIAISON IAM (250.1 KB)
03/06/14 - 2:00
DiaSorin launches the test for Vitamin D 1,25 on LIAISON (265.57 KB)
09/05/14 - 2:00
The Board of Directors approves the results for Q1'14 (573.05 KB)
23/04/14 - 2:00
Shareholders' meeting approves FY Results 2013 (107.65 KB)
06/03/14 - 1:00
The Board of Directors approves the results for FY'13 (753.73 KB)
18/02/14 - 1:00
DiaSorin launches the new test for PTH on LIAISON (597.92 KB)
11/02/14 - 1:00
DiaSorin launches the test for Rotavirus on stool sample (573.97 KB)
28/01/14 - 1:00
DiaSorin extends its master agreement with Laboratory Corporation of America Holdings till 2018 (336.26 KB)
24/01/14 - 1:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in China (579.02 KB)
09/01/14 - 1:00
DiaSorin launches the test for Cytomegalovirus on LIAISON IAM (174.61 KB)
08/11/13 - 1:00
The Board of Directors approves the Q3'13 Results (766.57 KB)
29/10/13 - 1:00
DiaSorin signes a 5-year agreement with Roche (432.42 KB)
25/10/13 - 2:00
DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
10/10/13 - 2:00
DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
24/09/13 - 2:00
DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
01/08/13 - 2:00
The Board of Directors approves the results for the H1 '13 (386.67 KB)
24/07/13 - 2:00
DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
11/07/13 - 2:00
DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
28/06/13 - 2:00
DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
20/06/13 - 2:00
DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
10/05/13 - 2:00
The Board of Directors approves the results for Q1'13 (763.61 KB)
02/05/13 - 2:00
Compensation Commitee-Errata corrige (179.38 KB)
22/04/13 - 2:00
Shareholders' meeting approves FY Results 2012 (57.22 KB)
17/04/13 - 2:00
FDA approves the Aldosterone assay (439.58 KB)
02/04/13 - 2:00
DiaSorin signs an agreement with Seegene (243.64 KB)
08/03/13 - 1:00
The BoD approves FY 2012 results (477.24 KB)
07/03/13 - 1:00
Notification of changes in share capital (46.86 KB)
07/03/13 - 1:00
Notice availability By-Laws (36.87 KB)
07/02/13 - 1:00
Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
07/02/13 - 1:00
Notification of changes in share capital (46.89 KB)
07/02/13 - 1:00
Notice availability By-Laws (139.13 KB)
30/01/13 - 1:00
The Board of Directors approves the results for the FY '12 (477.24 KB)
29/01/13 - 1:00
Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
20/12/12 - 1:00
Shareholders' meeting (55.42 KB)
07/11/12 - 1:00
The BoD approves Q3'12 results (280.42 KB)
03/08/12 - 2:00
The BoD approves H1'12 results (279.41 KB)
30/07/12 - 2:00
DiaSorin in India: JV with Trivitron Healthcare (56.16 KB)
27/06/12 - 2:00
Notification of changes in share capital (335.97 KB)
11/05/12 - 2:00
The BoD approves Q1'12 results (122.04 KB)
04/05/12 - 2:00
NorDiag acquisition (88.87 KB)
23/04/12 - 2:00
2011 statutory financial statement approval (182.29 KB)
10/04/12 - 2:00
Measles and Mumps IgM on LIAISON (available outside the US and Canada only) (43.59 KB)
02/04/12 - 2:00
Helicobacter Pylori on stool on LIAISON (available outside the US and Canada only) (43.85 KB)
30/03/12 - 2:00
Financial calendar update (176.51 KB)
22/03/12 - 1:00
Stock options to employees (175.38 KB)
12/03/12 - 1:00
Agreement with Sonic Healthcare on Vitamin D (179.85 KB)
09/03/12 - 1:00
The BoD approves FY 2011 results (357.11 KB)
07/03/12 - 1:00
Notification of changes in share capital (46.84 KB)
17/02/12 - 1:00
DiaSorin became a member of the ISBT (178.96 KB)
09/02/12 - 1:00
Notice of change in share capital (46.97 KB)
02/02/12 - 1:00
FDA clearance for 25 OH Vitamin D on LIAISON (180.35 KB)
27/01/12 - 1:00
2012 Financial calendar update (177.74 KB)
25/01/12 - 1:00
Dividend distribution in June (115.61 KB)
19/01/12 - 1:00
Prize for best Italian Company in R&D in the UK (183.95 KB)
13/01/12 - 1:00
2012 Financial calendar (176.51 KB)
12/01/12 - 1:00
New anti HBs II (available outside the US and Canada only) (196.83 KB)
23/12/11 - 1:00
Financial instruments to employees (57.22 KB)
19/12/11 - 1:00
Clostridium Difficile toxins A and B in stool on LIAISON (available outside the US and Canada only) (192.66 KB)
19/11/11 - 1:00
Buy-back plan (35.47 KB)
18/11/11 - 1:00
Financial instruments to employees (56.82 KB)
11/11/11 - 1:00
The BoD approves Q3'11 results (334.35 KB)
28/10/11 - 2:00
Buy-back plan (103.99 KB)
25/10/11 - 2:00
Buy-back plan (104.72 KB)
18/10/11 - 2:00
Buy-back plan (136.18 KB)
17/10/11 - 2:00
2011-2015 Business Plan: a new business wave (195.1 KB)
10/10/11 - 2:00
New Chief Financial Officer (196.26 KB)
06/10/11 - 2:00
Cardinal Health: agreement extended to 2014 (192.57 KB)
04/10/11 - 2:00
Buy-back plan (204.92 KB)
01/09/11 - 2:00
Resignation of Chief Financial Officer (177.77 KB)
31/08/11 - 2:00
2011 Financial calendar update (176.4 KB)
03/08/11 - 2:00
The BoD approves H1'11 results (324.48 KB)
11/07/11 - 2:00
Voluntarily removal from the STAR segment (194.93 KB)
13/05/11 - 2:00
The BoD approves Q1'11 results (307.28 KB)
11/05/11 - 2:00
DiaSorin and Labcorp extend strategic business relationship (100.01 KB)
06/05/11 - 2:00
Agreement with Precision System Science Co., LTD (171.54 KB)
28/04/11 - 2:00
The Ordinary Shareholders' meeting approves the 2010 statutory financial statements and the dividend distribution (175.61 KB)
16/03/11 - 1:00
The BoD approves FY'10 results (368.28 KB)
16/03/11 - 1:00
Dividend information amendment (159.83 KB)
28/02/11 - 1:00
2011 Financial calendar update (179.92 KB)
19/02/11 - 1:00
Notice of change in share capital (5.28 KB)
18/02/11 - 1:00
Buy-back plan (134.06 KB)
17/02/11 - 1:00
Financial instruments to employees (56.37 KB)
16/02/11 - 1:00
Buy-back plan (105.2 KB)
15/02/11 - 1:00
Buy-back plan (91.38 KB)
14/02/11 - 1:00
The BoD approves Q4'10 results (161 KB)
31/01/11 - 1:00
Buy-back plan (105.05 KB)
29/01/11 - 1:00
Buy-back plan (105.2 KB)
28/01/11 - 1:00
Buy-back plan (105.04 KB)
27/01/11 - 1:00
Buy-back plan (105.04 KB)
26/01/11 - 1:00
FDA approves the LIAISON XL (194.2 KB)
25/01/11 - 1:00
Buy-back plan (105.22 KB)
24/01/11 - 1:00
Buy-back plan (104.72 KB)
21/01/11 - 1:00
Buy-back plan (105.05 KB)
20/01/11 - 1:00
Buy-back plan (91.39 KB)
19/01/11 - 1:00
Buy-back plan (105.31 KB)
18/01/11 - 1:00
Buy-back plan (35.47 KB)
17/01/11 - 1:00
Buy-back plan (134.01 KB)
17/01/11 - 1:00
The Sonic Healthcare Group chooses DiaSorin (181.71 KB)
16/01/11 - 1:00
2011 Financial calendar (179.49 KB)
22/12/10 - 1:00
2011 Financial calendar (180.28 KB)
20/12/10 - 1:00
Dividend may be distributed in June (445.78 KB)
02/12/10 - 1:00
Comment on position Paper on Vitamin D (53.46 KB)
24/11/10 - 1:00
Change in share capital (46.85 KB)
18/11/10 - 1:00
Financial instruments to employees (48.33 KB)
05/11/10 - 1:00
The BoD approves Q3'10 results (414.16 KB)
02/11/10 - 1:00
Change in share capital (313.61 KB)
08/10/10 - 2:00
2010 Financial calendar update (174.1 KB)
30/09/10 - 2:00
Change in share capital (5.25 KB)
24/09/10 - 2:00
Financial instruments to employees (48.81 KB)
16/09/10 - 2:00
Stock options exercised by key managers (195.67 KB)
02/09/10 - 2:00
Financial instruments to employees (24.27 KB)
06/08/10 - 2:00
The BoD approves H1'10 results (287.11 KB)
07/07/10 - 2:00
Agreement with Meridian Inc. (182.7 KB)
06/07/10 - 2:00
2010 Financial calendar update (174.1 KB)
02/07/10 - 2:00
Financial instruments to employees (24.37 KB)
01/06/10 - 2:00
Acquisition of MUREX product line (102.6 KB)
14/05/10 - 2:00
The BoD approves Q1'10 results (254.05 KB)
27/04/10 - 2:00
Approval of statutory financial statements (182.99 KB)
20/04/10 - 2:00
2010 Financial calendar update (168.23 KB)
14/04/10 - 2:00
Postponement of the term for lists of members of the Board of Auditors (40.34 KB)
09/04/10 - 2:00
China approves new prenatal screening product line on LIAISON (141.08 KB)
02/04/10 - 2:00
Financial instruments to employees (27.79 KB)
22/03/10 - 1:00
The BoD approves FY 2009 results (306.02 KB)
10/03/10 - 1:00
Acquisition of MUREX product line (45.5 KB)
01/03/10 - 1:00
2010 Financial calendar update (192.49 KB)
12/02/10 - 1:00
The BoD approves Q4'09 results (213.8 KB)
18/01/10 - 1:00
2010 Financial calendar (103 KB)
24/12/09 - 1:00
Financial instruments to employees (26.76 KB)
30/10/09 - 1:00
The BoD approves Q3'09 results (212.92 KB)
12/10/09 - 2:00
Strengthening of group's R&D team (99.72 KB)
08/10/09 - 2:00
2009 Financial calendar update (97.3 KB)
05/10/09 - 2:00
Financial instruments to employees (27.08 KB)
06/08/09 - 2:00
The BoD approves H1'09 results (214.79 KB)
08/06/09 - 2:00
2009 Financial calendar update (97.33 KB)
18/05/09 - 2:00
Financial instruments to employees (26.65 KB)
10/04/09 - 2:00
Corporate Governance Report at December 2008. (97.57 KB)
08/04/09 - 2:00
2009 Financial calendar update (103.88 KB)
19/03/09 - 1:00
The BoD approves FY 2008 results (221.59 KB)
20/02/09 - 1:00
Financial instruments to employees (26.39 KB)
13/02/09 - 1:00
The BoD approves Q4'08 results (170.79 KB)
28/01/09 - 1:00
2009 Financial calendar (93.96 KB)
08/01/09 - 1:00
FDA clearance to five LIAISON products (96.84 KB)
23/12/08 - 1:00
Financial instruments to employees (26.19 KB)
21/11/08 - 1:00
Financial instruments to employees (23.66 KB)
13/11/08 - 1:00
The BoD approves Q3'08 results (171.93 KB)
22/09/08 - 2:00
Agreement in Japan with Advanced Life Science Institute (99.16 KB)
08/08/08 - 2:00
The BoD approves H1'08 results (194.3 KB)
09/07/08 - 2:00
Acquisition of Biotrin (99.08 KB)
16/05/08 - 2:00
Financial instruments to employees (23.28 KB)
15/05/08 - 2:00
Results for Q1'08 (159.78 KB)
24/04/08 - 2:00
2007 statutory financial Statements approved (93.67 KB)
21/04/08 - 2:00
2008 Financial calendar update (93.56 KB)
19/03/08 - 1:00
The BoD approves FY 2007 results (198.25 KB)
14/02/08 - 1:00
The BoD approves Q4'07 results (170.91 KB)
29/01/08 - 1:00
2008 Financial calendar (88.78 KB)
07/01/08 - 1:00